Bone-Muscle Research Center, College of Nursing & Health Innovation, University of Texas-Arlington, 655 W. Mitchell Street, Arlington, TX, 76010, USA.
Department of Bioengineering, University of Texas-Dallas, 800 W. Campbell Road, Richardson, TX, 75080, USA.
Sci Rep. 2021 Mar 23;11(1):6589. doi: 10.1038/s41598-021-86079-4.
The aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles. We designed the study according to PRISMA guidelines. Studies for qualitative and quantitative analyses were selected according to the following inclusion criteria: English language; size of sample (> 5 patients), adult (> age of 18) patients, treated with CQ/HCQ for inflammatory diseases, and presenting and not presenting with toxic effects on skeletal muscles. We collected data published from 1990 to April 2020 using PubMed, Cochrane Library, EMBASE, and SciELO. Risk of bias for observational studies was assessed regarding the ROBIN-I scale. Studies with less than five patients (case reports) were selected for an additional qualitative analysis. We used the software Comprehensive Meta-Analysis at the confidence level of 0.05. We identified 23 studies for qualitative analysis (17 case-reports), and five studies were eligible for quantitative analysis. From case reports, 21 patients presented muscle weakness and confirmatory biopsy for CQ/HCQ induced myopathy. From observational studies, 37 patients out of 1,367 patients from five studies presented muscle weakness related to the use of CQ/HCQ, and 252 patients presented elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase). Four studies presented data on 34 patients with confirmatory biopsy for drug-induced myopathy. No study presented randomized samples. The chronic use of CQ/HCQ may be a risk for drug-induced myopathy. There is substantiated need for proper randomized trials and controlled prospective studies needed to assess the clinical and subclinical stages of CQ/HCQ -induced muscle myopathy.
本系统评价的目的是对氯喹(CQ)和羟氯喹(HCQ)对骨骼肌的毒性作用进行定性和定量分析。我们根据 PRISMA 指南设计了这项研究。定性和定量分析的研究是根据以下纳入标准选择的:英语;样本量(>5 例患者),成人(>18 岁)患者,用 CQ/HCQ 治疗炎症性疾病,且存在或不存在骨骼肌毒性作用。我们使用 PubMed、Cochrane 图书馆、EMBASE 和 SciELO 从 1990 年至 2020 年 4 月收集发表的数据。使用 ROBIN-I 量表评估观察性研究的偏倚风险。选择少于 5 例患者(病例报告)进行额外的定性分析。我们在置信水平为 0.05 下使用 Comprehensive Meta-Analysis 软件进行分析。我们确定了 23 项定性分析研究(17 项病例报告),5 项研究符合定量分析标准。从病例报告中,21 例患者出现肌肉无力,并对 CQ/HCQ 诱导的肌病进行了确认性活检。从观察性研究中,5 项研究中的 37 例患者在使用 CQ/HCQ 时出现与肌肉无力相关的症状,252 例患者的肌肉酶(醛缩酶、肌酸磷酸激酶和乳酸脱氢酶)水平升高。4 项研究报告了 34 例经确认性活检诊断为药物诱导性肌病患者的数据。没有研究报告随机样本。CQ/HCQ 的慢性使用可能是药物诱导性肌病的一个风险因素。有充分的证据表明,需要进行适当的随机试验和对照前瞻性研究,以评估 CQ/HCQ 诱导的肌肉肌病的临床和亚临床阶段。